Research location
Bainbridge
Georgia, United States
Advertisement
Research activity in Bainbridge
Georgia, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 7 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bainbridge
7 linked trials · page 1 of 1Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesNCT02730377 · 2016-03-28 · 1 site observation
COMPLETED
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)NCT02642159 · 2016-03-15 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.NCT02648204 · 2016-01-06 · 1 site observation
COMPLETED
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)NCT01897532 · 2013-07-10 · 1 site observation
COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive MedicationNCT01195662 · 2010-10-01 · 1 site observation
COMPLETED
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerNCT01137474 · 2010-07-01 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 2 site observations
COMPLETED
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.